Join our daily newsletter At The Bell to receive exclusive market insights
- Immuron (IMC) announces a 136 per cent increase in FY23 global sales on FY22 sales
- The sales of its over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn rose from $765,000 in FY22 to $1.80 million in FY23
- Australian FY23 sales were up 478 per cent on FY22 sales, while US Travelan sales were up 28 per cent on FY22 sales
- Immuron is focused on growing sales of its commercial products, as well as expanding its portfolio of products
- Shares rose 4.11 per cent to 7.6 cents at market close
Immuron (IMC) has announced that its FY23 global sales have increased by 136 per cent on FY22 sales.
Sales of the company’s over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn rose from $765,000 in FY22 to $1.80 million in FY23.
Australian sales saw a 478 per cent increase from $201,000 in FY22 to $1.16 million in FY23.
Australian exact sales of Travelan however, cannot be released until the company has received GMP clearance from the Therapeutic Goods Administration.
US sales of Travelan were up 28 per cent from FY22, rising from $501,000 to $643,000 in FY23.
The rise in the US was attributed to increasing sales in both passport health travel clinics and distributor sales.
Immuron remains focused on growing the sales of its commercial products, as well as expanding its portfolio of products.
IMC shares rose 4.11 per cent to 7.6 cents at market close.
